At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Metformin on Mood and Cognition During Nicotine Withdrawal
In Brief
A Phase 2 clinical trial evaluating Metformin and Placebo for Smoking and HIV-1-infection. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The purpose of this study is to test the effects of a medication called metformin (Glucophage®) on smoking behavior. This medication is FDA-approved for treatment of type-2 diabetes. It is being used for research purposes in this study. Participants will be randomized to one of 3 treatment groups: low dose of metformin, high dose of metformin, or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking, HIV-1-infection
CountriesUnited States
CollaboratorsPennsylvania Department of Health
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedJul 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedJul 20, 2018
Enrollment StartApr 1, 2016
Primary CompletionMar 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.0 years ago
Interventions
Metformindrug
Metformin capsule
Placebodrug
Sucrose filler in gel capsules